Adipose-derived mesenchymal stem cells attenuate dialysis-induced peritoneal fibrosis by modulating macrophage polarization via interleukin-6.
Chih-Yu YangPu-Yuan ChangJun-Yi ChenBo-Sheng WuAn-Hang YangOscar Kuang-Sheng LeePublished in: Stem cell research & therapy (2021)
In dialysis-induced peritoneal fibrosis, MSCs are situated in an inflammatory environment of TGF-β1 and secrete IL-6 to polarize macrophages into the M2 phenotype. Our findings reveal a previously unidentified role of tissue macrophage in this antifibrotic process. ADSC has the advantage of abundance and accessibility, making the application values extremely promising. In dialysis-induced peritoneal fibrosis, peritoneal mesothelial cells secrete transforming growth factor-β1 (TGF-β1) when exposed to methylglyoxal (MGO)-containing peritoneal dialysate. When situated in TGF-β1, the inflammatory environment induces mesenchymal stem cells to secrete interleukin-6 (IL-6), IL-6 polarizes macrophages into the M2 phenotype. The dominant peritoneal tissue M2 macrophages, marked by upregulated Arg-1 expression, account for the attenuation of MGO-induced dedifferentiation of peritoneal mesothelial cells to maintain epithelial integrity.
Keyphrases
- transforming growth factor
- high glucose
- mesenchymal stem cells
- diabetic rats
- epithelial mesenchymal transition
- chronic kidney disease
- umbilical cord
- oxidative stress
- poor prognosis
- cell cycle arrest
- gene expression
- adipose tissue
- cell death
- cell proliferation
- genome wide
- dna methylation
- cell therapy
- microbial community
- peritoneal dialysis
- liver fibrosis
- anaerobic digestion